Alentis Therapeutics has raised a $105M Series C funding round to develop therapies for patients with tumors and organ fibrosis.

 

Alentis Therapeutics has raised a $105M Series C funding round to develop therapies for patients with tumors and organ fibrosis.  The company has raised $190M since being founded in 2018. Alentis is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis.  The company aims to use the funding for the clinical development of its lead investigational products: ALE.F02 and ALE.C04. This funding round was led by Jeito Capital, with participation from Novo Holdings A/S, RA Capital Management, BB Pureos Bioventures, InnoBio Fund 2, and Schroders Capital.  The company is headquartered in Basel, Switzerland.